Antibody-drug Conjugates (ADC)

NHS-Ala-Ala-Asn-active metabolite is a cleavable linker specifically designed for antibody-drug conjugates (ADCs), targeting kinesin spindle protein (KSP) inhibitors. This reagent facilitates the synthesis of ADCs by ensuring effective drug delivery to cancer cells through selective cleavage. Its key applications include the development and optimization of targeted cancer therapies, enhancing therapeutic efficacy while minimizing off-target effects.

Fmoc-PEG3-Ala-Ala-Asn(Trt)-PAB-PNP is a cleavable linker designed for the synthesis of antibody-drug conjugates (ADCs). This compound facilitates the selective release of cytotoxic agents upon internalization by target cells, enhancing the therapeutic efficacy of ADCs. It is ideal for applications in cancer research and the development of targeted therapies.

NH2-PEG3-Val-Cit-PAB-OH is a cleavable antibody-drug conjugate (ADC) linker that incorporates a primary amine, a hydrophilic PEG spacer, a Val-Cit dipeptide, and a PAB group. This compound is designed to enhance payload delivery by undergoing cleavage by cellular proteases, facilitating the release of the drug inside the target cells. The primary amine allows for versatile functionalization through reactions with carboxylic acids, reductive aminations, and various advanced coupling techniques, making it suitable for applications in drug development and targeted therapies.

t-Boc-N-amido-PEG4-Val-Cit is a protease-cleavable linker designed for antibody-drug conjugates (ADCs). This compound consists of a Boc-protected amine, a hydrophilic polyethylene glycol (PEG) spacer, and a Val-Cit dipeptide that can be cleaved by cellular proteases. The resulting carboxylic acid facilitates coupling reactions with amines to form amides. Upon removal of the Boc group under acidic conditions, a free primary amine is available for diverse chemical reactions, including coupling and reductive amination, making it a versatile tool in ADC development and modification.

NH2-PEG1-Val-Cit-PAB-OH is a cleavable antibody-drug conjugate (ADC) linker designed for efficient payload delivery. This reagent features a primary amine, a hydrophilic PEG spacer, a Val-Cit dipeptide, and a PAB group, enabling versatile coupling reactions with carboxylic acids, ketones, and aldehydes. The Val-Cit dipeptide undergoes proteolytic cleavage within cells, facilitating the release of drug payloads through an elimination mechanism associated with the PAB structure. This compound is ideal for ADC development and other related bioconjugation applications.

N-Boc-MeVal is an ADC linker featuring a BOC protecting group. This compound is utilized in the development of antibody-drug conjugates (ADCs), facilitating the stable attachment of cytotoxic agents to antibodies for targeted cancer therapies. Its chemical structure allows for efficient conjugation, enhancing the efficacy and selectivity of therapeutic agents in research applications focused on oncology and drug delivery systems.

BCN-exo-PEG2-NH2 is an ADC linker featuring two polyethylene glycol (PEG) units. This compound incorporates the hydrophilic bidentate macrocyclic ligand, BCN, facilitating the formation of macrocyclic complexes. In click chemistry applications, BCN efficiently reacts with azide-containing molecules, yielding stable triazoles without the need for catalysts, making it valuable for antibody-drug conjugate (ADC) development and other bioconjugation strategies.

NH2-PEG4-Val-Cit-PAB-OH is a cleavable antibody-drug conjugate (ADC) linker designed for targeted delivery of therapeutic payloads. Its structure includes a primary amine for versatile coupling reactions, a hydrophilic PEG spacer, and a Val-Cit dipeptide that is readily cleaved by cellular proteases, facilitating the release of the drug inside target cells. The PAB moiety enables efficient attachment of reactive groups, enhancing conjugation with drug payloads. This linker is valuable in research applications involving ADC development and optimization, enabling precise targeting in cancer therapy.

MC-GGFG-3-Methylenecyclobutyl functions as an ADC linker, facilitating the development of antibody-drug conjugates (ADCs). This compound enables stable conjugation between antibodies and cytotoxic drugs, enhancing targeted delivery to cancer cells. Its structural properties are designed to improve the efficacy and safety profile of therapeutic agents in cancer research and treatment.

(2R,3S)-3-(tert-Butoxy)-2-(4-ethyl-2,3-dioxopiperazine-1-carboxamido)butanoic acid serves as a versatile antibody-drug conjugate (ADC) linker. This compound is designed to facilitate the selective delivery of cytotoxic agents, enhancing the efficacy of targeted therapies. Its unique chemical structure promotes stability and solubility, making it suitable for various applications in oncology research and drug development.

Propargyl-PEG4-CH2CO2-NHS is an ADC linker that features a propargyl group and an N-hydroxysuccinimidyl (NHS) moiety. This compound facilitates the synthesis of antibody-drug conjugates (ADCs) by enabling selective coupling with amine-containing biomolecules. As a click chemistry reagent, it contains an alkyne functional group, allowing for efficient copper-catalyzed azide-alkyne cycloaddition (CuAAc) reactions with azide-containing partners. This versatile tool is essential for enhancing the potency and specificity of targeted therapeutics in bioconjugation applications.

Boc-PEG2-Val-Cit-PAB-OH is an enzyme-cleavable linker designed for antibody-drug conjugates (ADCs). The compound features a Boc-protected amine, a flexible PEG spacer, and a Val-Cit-PAB dipeptide, facilitating targeted delivery. The benzylic alcohol on the PAB moiety allows for the attachment of reactive groups for conjugation with drug payloads. Upon exposure to acidic conditions, the Boc group is removed to yield a primary amine for subsequent coupling reactions. The Val-Cit-PAB component is readily cleaved by cellular proteases, enabling the efficient release of therapeutic agents within target cells.

BCN-endo-PEG7-NH2 is a bifunctional ADC linker featuring a 7-unit PEG spacer and the lipophilic macrocyclic ligand endo-BCN. This compound enables efficient conjugation through click chemistry, allowing stable triazole formation with azide-containing molecules without the need for catalysts. BCN-endo-PEG7-NH2 is suitable for applications in antibody-drug conjugate (ADC) development and other bioconjugation techniques, facilitating targeted delivery and enhancing therapeutic efficacy in chemical biology research.

Alloc-Val-Ala-PAB-PNP is a cleavable ADC linker that facilitates targeted delivery of therapeutic agents. This compound effectively promotes the controlled release of payloads in targeted cells, enhancing specificity and minimizing off-target effects. It is particularly useful in the development of antibody-drug conjugates (ADCs) for cancer therapy, enabling researchers to investigate novel treatment strategies.

Alkyne-Val-Cit-PAB-PNP is a cleavable linker designed for antibody-drug conjugates (ADCs). This compound facilitates stable attachment of cytotoxic agents to antibodies while enabling release in the target tissues or cells via specific enzymatic cleavage. Its properties make it suitable for research applications focused on enhancing the efficacy and selectivity of ADCs in cancer therapy and related studies.

Mal-amido-PEG8-val-gly is a maleimide-based linker designed for antibody-drug conjugates (ADCs). This compound facilitates site-specific conjugation to thiol-containing biomolecules, enhancing the stability and therapeutic efficacy of the ADCs. It is particularly useful in the development of targeted cancer therapies by linking cytotoxic agents to antibodies, thereby enabling precise delivery to tumor cells.

(Ac)Phe-Lys(Alloc)-PABC-PNP is a cleavable chemical linker designed for use in antibody-drug conjugates (ADCs). It facilitates targeted delivery of therapeutic agents by linking the antibody to the drug while ensuring controlled release upon reaching the target site. This linker is valuable in the development of ADCs, enhancing their efficacy and minimizing off-target effects in cancer research and therapy.

Azido-PEG4-Ala-Ala-Asn(Trt)-PAB is a cleavable linker specifically designed for antibody-drug conjugates (ADCs). This compound facilitates the conjugation of antibodies to cytotoxic drugs, enhancing targeted delivery in cancer therapy. Its unique structure allows for selective cleavage in tumor environments, leading to effective drug release and improved therapeutic efficacy. Research applications include the development of novel ADCs and the exploration of targeted delivery mechanisms in oncology research.

Mal-amide-PEG8-Val-Cit-PAB-PNP is a cleavable antibody-drug conjugate (ADC) linker that targets thiol groups through its maleimide component, enabling selective labeling of cysteine residues in proteins. This linker incorporates an 8-unit polyethylene glycol (PEG) spacer for improved solubility and a Val-Cit dipeptide that is susceptible to cleavage by cytoplasmic peptidases, facilitating controlled drug release. The PAB and PNP carbonate groups enhance the linker’s reactivity, making it suitable for developing potent and targeted therapeutic agents in cancer research and other applications involving ADCs.

cBu-Cit-PAB is a crucial intermediate in the synthesis of antibody-drug conjugates (ADCs). It serves as a versatile linker that facilitates the attachment of cytotoxic agents to antibodies, enhancing targeted drug delivery. This compound is essential for research applications focused on developing innovative ADC formulations for cancer treatment.

Mm-C3-OSu (Methyl Maleate-C3-N-Hydroxysuccinimide Ester) serves as a chemically defined linker intermediate, featuring a cis-configured methyl maleate core with a C3 alkyl chain that is capped with an N-hydroxysuccinimide reactive group. This compound is specifically designed for the synthesis of stable antibody-drug conjugates (ADCs), facilitating targeted drug delivery in therapeutic applications. Its structural properties enable efficient conjugation, enhancing the stability and efficacy of ADC formulations in research and development.

NH2-PEG6-Val-Cit-PAB-OH is a cleavable antibody-drug conjugate (ADC) linker that incorporates a primary amine, a PEG spacer, a Val-Cit dipeptide, and a PAB group. This design facilitates the attachment of reactive groups, enabling the conjugation of drug payloads through the benzylic alcohol on the PAB moiety. The primary amine allows for versatile reactions, including coupling with carboxylic acids and reductive aminations. Within cells, the Val-Cit dipeptide is cleaved by proteases, promoting efficient drug release via the elimination mechanism inherent to the PAB structure, thus enhancing therapeutic efficacy in targeted delivery applications.

SCO-PEG7-Maleimide is a cleavable ADC linker incorporating three polyethylene glycol (PEG) units. This compound is designed for use in antibody-drug conjugates, facilitating targeted drug delivery. Its maleimide functional group enables efficient conjugation in aqueous environments, making it suitable for catalyst-free click chemistry applications. SCO-PEG7-Maleimide has significant utility in drug delivery research, particularly in studies focused on enhancing therapeutic efficacy and specificity.

Biotin-C2-S-S-pyridine is a cleavable linker designed for use in antibody-drug conjugates (ADCs). This compound facilitates the targeted delivery of cytotoxic agents to cancer cells by selectively releasing the drug upon internalization. Its biotin component allows for strong interactions with streptavidin-tagged proteins, enhancing the specificity and effectiveness of therapeutic applications in cancer research.

MC-Val-Cit-PAB-Ispinesib is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications, featuring a cleavable linker combined with the Eg5 inhibitor, ispinesib. This compound enables the targeted delivery of cytotoxic agents to tumor cells, enhancing therapeutic efficacy while minimizing off-target effects. Its unique structure facilitates the precise synthesis of ADCs, making it a valuable tool for cancer research and development.

Modified MMAF is an ADC cytotoxin that functions by disrupting microtubule dynamics, leading to cell cycle arrest and apoptosis in cancer cells. It is primarily utilized in the synthesis of Antibody-drug Conjugates (ADCs), enhancing the specificity and efficacy of targeted cancer therapies. This compound is a valuable tool for research applications focused on cancer treatment modalities and the development of targeted drug delivery systems.

INX-SM-3 is a specialized linker designed for antibody-drug conjugates (ADCs) that incorporates glucocorticosteroid functionality. This compound enables precise delivery of therapeutic agents, enhancing the efficacy of ADCs by leveraging the anti-inflammatory properties of glucocorticosteroids. Its unique structure allows for improved stability and bioactivity, making it suitable for research applications in targeted cancer therapy and immunology studies.

TCO-PEG3-Biotin is a cleavable linker designed for antibody-drug conjugate (ADC) synthesis, featuring a three-unit polyethylene glycol (PEG) backbone. This compound includes a trans-cyclooctene (TCO) moiety that facilitates click chemistry through an inverse electron demand Diels-Alder (iEDDA) reaction with tetrazine-containing molecules. TCO-PEG3-Biotin is valuable in conjugating biomolecules, enabling targeted drug delivery and enhancing therapeutic efficacy in various biological research applications.

PTAD-PEG4-alkyne is a cleavable linker designed for use in antibody-drug conjugate (ADC) synthesis. This 4-unit polyethylene glycol (PEG) linker features an alkyne functional group, enabling it to participate in copper-catalyzed azide-alkyne cycloaddition (CuAAc) with azide-containing compounds. Its unique properties facilitate the targeted delivery of therapeutic agents, making it a valuable tool in the development of ADCs for research applications in cancer therapeutics and other fields.

Fmoc-NH-PEG6-alcohol is a cleavable linker specifically designed for the synthesis of antibody-drug conjugates (ADCs). This reagent plays a crucial role in enhancing the efficacy and specificity of ADCs by facilitating the controlled release of cytotoxic agents upon internalization. Its structure promotes solubility and stability, making it suitable for various research applications, including cancer therapeutics and targeted drug delivery studies.

P5(PEG24)-OSu is a polyethylene glycol (PEG) linker designed for antibody-drug conjugate (ADC) applications. This reagent facilitates the synthesis of PROTAC molecules, promoting targeted protein degradation. Its PEGylated structure enhances solubility and improves pharmacokinetic properties, making it a valuable tool in therapeutic research and development focused on precision medicine.

Tr-PEG4-OH is a non-cleavable four-unit polyethylene glycol (PEG) linker designed for use in antibody-drug conjugates (ADCs). Its stable structure facilitates the conjugation of cytotoxic agents to antibodies, enhancing the therapeutic efficacy while minimizing off-target effects. This linker is ideal for research applications involving ADC development and optimization for targeted cancer therapies.